Investors in Science

Kurma Partners is a leading European venture capital group specializing in healthcare, managing €470 million in assets. Our firm operates through two dedicated franchises: Kurma Biofund, which focuses on therapeutics (currently active with fund KBIII), and Kurma Diagnostics, which focuses on diagnostic and digital health (currently active with fund Kurma Dx2). We are committed to supporting innovation in healthcare by investing in promising companies that are poised to make significant advancements in therapeutic treatments and diagnostic technologies.

redalpine is the Swiss venture capital firm that empowers GameChangers. Founded in 2006, redalpine brings together financial investment, operational expertise, and a vast international network to help ambitious entrepreneurs transform their vision into a reality. With over €1bn in assets under management and a disciplined, sector-agnostic investment strategy, the firm has backed some of Europe's most disruptive companies, including N26, Taxfix, Inkitt, 9fin, Carvolution, Zenjob, vivenu, and Umiami. redalpine has over 95 companies in its portfolio and invests Europe-wide from its offices in Zurich and Berlin.

Integra Holdings is a unique venture fund that combines academic excellence, funding and R&D guidance together with a strong and proven business network — the most important elements necessary to bring academic innovation to the market. Focusing on an exclusive selection of biotech companies with proprietary solutions and a competitive advantage in their respective fields, Integra takes a hands-on approach by providing our portfolio companies the strategic planning and business development necessary to bring their technology to the market. Founded by Yissum, the Hebrew University's technology transfer company, Integra capitalizes on the innovative applied research constantly flowing from the renowned Hebrew University of Jerusalem, Israel.

We support early-stage biotech and longevity-focused founders that are changing the world. We help these companies gain industrial momentum, raise capital, and shape the future of biotech. Our approach is based on growing the whole ecosystem. We fund companies in complementary industrial sectors, empowering us to build a broad community of biotech innovators that can exchange their expertise and build on each other's successes.

Healthcare & Technology Venture Capital since 2001. Vi Partners is the longest-established Swiss Venture Capital firm. For more than 20 years, Vi Partners has been supporting innovative Technology and Healthcare companies, investing over CHF 330m in 66 startups. Vi Partners-managed funds are backed by Switzerland's most visible companies and institutions, including ETH Zurich, ABB, Buhler, Credit Suisse, Hilti, McKinsey, Nestlé, Schindler, Sulzer, Suva and ZKB as well as the European Investment Fund and many other institutional investors.

Since 1998, we at Auriga Partners have supported entrepreneurs from the creation of their company through all stages of development, up to their exit via merger and acquisition or IPO. As pioneers in venture capital in France, we have reinvented ourselves into a multi-specialist investor, dedicated to bringing together specific expertise on future themes or territories—both in unlisted and listed companies.

i&i Prague is a bio-innovation center partner for biotech innovations and smart money investments.i&i Prague is located in the heart of Europe, specializing in identifying and investing in new inventions in Drug Discovery, Diagnostics, MedTech, and other Life Science fields. They support projects from academic institutions.

We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options. Our focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and Benelux. We mostly invest in drug development and, to a lesser degree, in diagnostics and medical technology. The amount we aim to invest over the life time of our portfolio companies is up to CHF 10 million.

Aravis is an independent Swiss on-shore private equity fund manager. With our entrepreneurial experience, we take leading positions in our invested portfolio companies and understand the balance between finance, commercial assets and people. We have expanded our team expertise from biotech, renewable energy and luxury goods to creative and digital space as well as industrial high-tech. Our fifth fund focuses on Swiss growth companies that are commercially established (more than CHF 5m turnover) and in need of capital to expand their product offering and enter new markets.

We believe hackers have the power to build valuable businesses that compete on a global scale. We don't break the rules, we rewrite them. Hook is our 4-month program designed to help founders during the most difficult time: starting. There are two batches a year: in Fall and Spring.

Beyond Impact VC www.beyondimpact.vc advises in the creation of portfolios that accelerate our transition to a cruelty-free world, with a focus on : Organic crop production and distribution Plant-based meat, fish and leather alternatives Vegan convenience foods «Clean» meat, fish and leather Vegan catering and restaurants Vegan clothing and accessories Vegan lifestyle businesses. Replacements for animal testing Cruelty-free, organic household products, toiletries and cosmetics

Headquartered in Paris and London, Óskare Capital specializes in venture-stage investments in the Deeptech and Life Sciences sectors.